Systematic Literature Review: Ability of the IBDQ-32 to Detect Meaningful Change in Ulcerative Colitis Health Indicators.

IBDQ responsiveness ulcerative colitis

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
27 Dec 2023
Historique:
received: 14 06 2023
medline: 27 12 2023
pubmed: 27 12 2023
entrez: 27 12 2023
Statut: aheadofprint

Résumé

Previous reviews produced weak evidence regarding the responsiveness of the Inflammatory Bowel Disease Questionnaire (IBDQ-32) to changes in ulcerative colitis (UC) health indicators. This systematic review and meta-analysis provide an updated synthesis on IBDQ-32 responsiveness. A systematic literature review identified 11 articles reporting IBDQ-32 responder analyses in randomized control trials, which were included in a random effects meta-analysis, and 15 articles linking IBDQ-32 change to change in UC health indicators, which were summarized narratively. Meta-analysis compared differences between IBDQ-32 responder proportions in efficacious and nonefficacious treatment arms relative to placebo. Linear meta-regression examined the association of treatment efficacy and proportions of IBDQ-32 responders in active treatment compared with placebo. Meta-analysis showed larger differences in IBDQ-32 response proportions between active treatment and placebo for efficacious treatments (pooled OR, 2.19; 95% CI, 1.83-2.63) than nonefficacious treatments (pooled OR, 1.21; 95% CI, 0.84-1.74; Cochran's Q[df = 1] = 8.26, P = .004). Meta-regression showed that the magnitude of treatment efficacy positively predicted IBDQ-32 response in active treatments relative to placebo (β = 0.21, P < .001). Moderate to strong correlations were found between change in IBDQ-32 and change in health indicators (eg, patient-reported measures, disease activity, endoscopic indices; correlations, 0.37-0.64 in absolute values). Patients achieving clinical response or remission showed greater change in IBDQ-32 total scores (range, 22.3-50.1 points) and more frequently met clinically meaningful thresholds on the IBDQ-32 than those not achieving clinical response or remission (all P < .05). The IBDQ-32 is responsive to changes in UC health indicators and disease activity, including in response to efficacious treatment (relative to placebo). This article presents a review of evidence on the responsiveness of the 32-item Inflammatory Bowel Disease Questionnaire, a widely used patient-report measure of health-related quality of life. W found a generally good ability of the instrument to detect changes in ulcerative colitis health that are meaningful to patients and clinicians.

Autres résumés

Type: plain-language-summary (eng)
This article presents a review of evidence on the responsiveness of the 32-item Inflammatory Bowel Disease Questionnaire, a widely used patient-report measure of health-related quality of life. W found a generally good ability of the instrument to detect changes in ulcerative colitis health that are meaningful to patients and clinicians.

Identifiants

pubmed: 38150386
pii: 7502662
doi: 10.1093/ibd/izad282
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Pfizer

Informations de copyright

© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Auteurs

Marla Dubinsky (M)

Icahn School of Medicine Mount Sinai, New York, NY, USA.

Alexander Rice (A)

QualityMetric Incorporated, LLC, Johnston, RI, USA.

Aaron Yarlas (A)

formerly of QualityMetric Incorporated, LLC, Johnston, RI, USA.

Peter Hur (P)

Pfizer Inc., New York, NY, USA.

Joseph C Cappelleri (JC)

Pfizer Inc., New York, NY, USA.

Nicole Kulisek (N)

Pfizer Inc., New York, NY, USA.

Audrey Fahrny (A)

Pfizer Inc., New York, NY, USA.

Andrew Bushmakin (A)

Pfizer Inc., New York, NY, USA.

Luc Biedermann (L)

University Hospital Zurich, Switzerland.

Classifications MeSH